Linagliptin and other DPP-4 inhibitors suppress DPP-4, a peptidase which cleaves hypoglycemia incretins secreted by intestinal L cells such as glucagon-like peptide (GLP)-1, thereby lowering the post-prandial blood glucose level [19,20]. The gene discussed is DPP4; the disease is Hypoglycemia.